StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $388.77K | $0.00 | $207.33K | $3.96K |
Operating Income | $-1.32M | $-9.05M | $-5.90M | $-4.10M |
Net Income | $4.25M | $-28.74M | $-21.05M | $-17.13M |
EPS (Diluted) | $0.43 | $-8.81 | $-9.84 | $-11.83 |
Total Assets | $31.05M | $25.84M | $18.36M | $19.79M |
Total Liabilities | $4.88M | $3.94M | $1.69M | $1.83M |
Cash & Equivalents | $3.65M | $5.50M | $1.45M | $14.37M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 7.47M | 7.45M | 4.53M | 2.50M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $5.85 | $5.78 | -1.20% | 0.2M |
| 05-15 | $5.36 | $5.22 | -2.61% | 0.3M |
| 05-18 | $5.03 | $4.79 | -4.77% | 0.2M |
| 05-19 | $4.67 | $4.54 | -2.78% | 0.1M |
| 05-20 | $4.53 | $4.60 | +1.55% | 0.2M |
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
No sell-side coverage available for TAOX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
TAOX is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.